In an apparent softening of its tough stance on the overseas transfer of personal data, China’s top data security regulatory agency, the Cybersecurity Administration of China (CAC), has issued a new proposal to make such transfers easier for foreign businesses, including pharma and biotech companies looking to conduct global clinical studies and transfer manufacturing-related information.
China May Ease Data Transfer Rules But Regulatory Ambiguity Remains
New Approach To 'Important Data'
China's latest proposed rules governing the overseas transfer of personal data may allow pharma, biotech and digital health companies to avoid regulatory security reviews and formal standard contracts, as well as personal information protection certification, but key definitions of “important data” and “negative list” items remain to be clarified.
